Q2 2012

13.08.2012 • News

Oxea Reports Robust Earnings and Strong Cash Flows

Oxea, a global supplier of Oxo Intermediates and Oxo Derivatives, today announced robust earnings for the second quarter of 2012, with net sales of €380 million getting close to prior year's level.

Top-Feature

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Photo
Oxea